Navigation Links
BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
Date:6/20/2012

Los Angeles, CA (PRWEB) June 20, 2012

BioRealm, LLC announced today that it has been awarded a Small Business Innovative Research contract by the U.S. National Institute on Drug Abuse (NIDA) to develop a universal genetic screening tool for tobacco addiction and treatment approaches. BioRealm’s “Smokescreen” product will integrate recent advances in tobacco addiction research and allow researchers to study thousands of an individual’s genetic variants related to tobacco dependence and treatment response.

According to the Centers for Disease Control and Prevention (CDC), smoking is the leading cause of preventable disease in the U.S., resulting in $96 billion in annual health care costs. Despite the availability of numerous smoking cessation products and treatments, effectiveness varies greatly and people often relapse. Studies have shown that genetic variation plays a significant role in nicotine dependence, including the ability to quit smoking and response to nicotine replacement therapy and medication. However, the genetics of tobacco addiction are not yet fully understood.

Addiction researchers have so far been limited by the small number of participants in clinical trials, and the lack of a validated genetic screening tool and centralized database for storing results. “The Smokescreen aims to solve these problems by featuring a uniform set of genetic variants, with genotyping results automatically stored and accessible via a secure cloud-based application”, stated Christopher Edlund, Bioinformatics Principal at BioRealm. “The ability to seamlessly share and compare data across multiple studies will enable researchers and clinicians to more effectively investigate tobacco addiction”.

Scientists at BioRealm envision the Smokescreen to be the standard genetic test used by clinical trials for smoking cessation. “The Smokescreen will be an invaluable resource for developing personalized smoking cessation treatments and ultimately reducing tobacco use in the U.S.”, said BioRealm co-founder Dr. James Baurley.

Additional information related to the Smokescreen product can be found at http://www.biorealmresearch.com/smokescreen.

About BioRealm

Founded in 2006, BioRealm develops solutions for genetic research and the biomedical industry.

Source: BioRealm, LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9621970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NASA develops super-black material that absorbs light across multiple wavelength bands
2. Gated STED -- developing the next generation of super-resolution microscopes
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Multidisciplinary team of researchers develop world’s lightest material
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
7. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
10. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
11. Researchers develop one of the worlds smallest electronic circuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, ... on enhancing productivity in aquaculture and a majority-owned subsidiary ... that it has completed the listing of its common ... equity subscription from Intrexon. "AquaBounty,s listing on ... will broaden our exposure to the U.S. markets as ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... services spanning the full spectrum of drug and device development, and Prism ... pharma/device companies and clinicians, today announced Verified Clinical Trials (VCT) has ...
(Date:1/19/2017)... N.J. , Jan. 18, 2017 BD (Becton, Dickinson ... company, announced today that it will host a live webcast of ... 1 p.m. (ET). The webcast can be accessed ... available for replay through Tuesday, January 31, 2017. ... About BD BD is ...
(Date:1/18/2017)... Jan. 18, 2017 Applied BioMath ( ... to drug research and development, today announced that ... and CEO of Applied BioMath, will present at ... Modeling (BAGIM) Meeting on Thursday January 19, 2017 ... , MA.   Dr. Burke,s talk "Quantitative Modeling ...
Breaking Biology Technology:
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):